Payment overview · 2025
General Payments
$135.41
6 reported records · 4 companies
Healthcare provider profile · identity verified
John P. Opilka, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · ALTAMONT, IL · NPI 1497715056
Verified facts
What the public records show
CMS Open Payments records show John P. Opilka, D.O. received $135.41 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 35.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.61 | 35.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.54 | 28.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.12 | 22.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.14 | 13.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $96.87 | 5 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.61 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $38.54 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 17 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 608 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 572 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 539 | 113 |
| Potassium Chloride | Potassium Chloride | 528 | 100 |
| Eliquis | Apixaban | 483 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 385 | 83 |
| Lisinopril | Lisinopril | 374 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 305 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 285 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 71 |
| Gabapentin | Gabapentin | 272 | 54 |
| Losartan Potassium | Losartan Potassium | 264 | 65 |
| Omeprazole | Omeprazole | 263 | 58 |
| Montelukast Sodium | Montelukast Sodium | 247 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 50 |
| Memantine Hcl | Memantine Hcl | 230 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 228 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 227 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 208 | 30 |
| Trazodone Hcl | Trazodone Hcl | 202 | 28 |
| Donepezil Hcl | Donepezil Hcl | 200 | 32 |
| Metformin Hcl | Metformin Hcl | 197 | 50 |
| Carvedilol | Carvedilol | 193 | 47 |
| Sertraline Hcl | Sertraline Hcl | 190 | 47 |
| Warfarin Sodium | Warfarin Sodium | 180 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 178 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 172 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 165 | 29 |
| Simvastatin | Simvastatin | 160 | 39 |
| Mirtazapine | Mirtazapine | 153 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 147 | 19 |
| Tramadol Hcl | Tramadol Hcl | 141 | 44 |
| Allopurinol | Allopurinol | 134 | 33 |
| Famotidine | Famotidine | 121 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 23 |
| Lorazepam | Lorazepam | 115 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 35 |
| Alprazolam | Alprazolam | 97 | 26 |
| Azithromycin | Azithromycin | 95 | 69 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 18 |
| Buspirone Hcl | Buspirone Hcl | 87 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 87 | 41 |
| Levetiracetam | Levetiracetam | 84 | 11 |
| Meloxicam | Meloxicam | 83 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 27 |
| Levofloxacin | Levofloxacin | 78 | 52 |
| Divalproex Sodium | Divalproex Sodium | 77 | 13 |
| Spironolactone | Spironolactone | 73 | 17 |
| Prednisone | Prednisone | 72 | 36 |
| Risperidone | Risperidone | 71 | suppressed |
| Jardiance | Empagliflozin | 66 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | suppressed |
| Cefdinir | Cefdinir | 61 | 47 |
| Xarelto | Rivaroxaban | 57 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 13 |
| Glipizide | Glipizide | 54 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | suppressed |
| Atenolol | Atenolol | 49 | 14 |
| Glipizide Er | Glipizide | 49 | suppressed |
| Lactulose | Lactulose | 49 | suppressed |
| Aripiprazole | Aripiprazole | 48 | suppressed |
| Cephalexin | Cephalexin | 48 | 34 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 48 | 17 |
| Nystatin | Nystatin | 46 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 16 |
| Paliperidone Er | Paliperidone | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Lovastatin | Lovastatin | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 33 |
| Fentanyl | Fentanyl | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 15 |
| Ezetimibe | Ezetimibe | 38 | 14 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 38 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 35 | 14 |
| Finasteride | Finasteride | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Enulose | Lactulose | 29 | suppressed |
| Metronidazole | Metronidazole | 29 | 11 |
| Baclofen | Baclofen | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 28 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 11 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 23 | 23 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 18 |
| Ondansetron Odt | Ondansetron | 21 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Nyamyc | Nystatin | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 18 |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 11 |
| Glimepiride | Glimepiride | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 14 |
| Temazepam | Temazepam | 14 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $135.41 · 6 records | ABBVIE INC. | FARXIGA, MOUNJARO, QULIPTA, REXULTI, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error